Go Pro
NASDAQ:JUNS

Jupiter Neurosciences Q1 2026 Earnings Report

Jupiter Neurosciences logo
$4.18 -0.71 (-14.52%)
As of 08/28/2026 04:00 PM Eastern

Jupiter Neurosciences EPS Results

Actual EPS
-$4.50
Consensus EPS
-$3.75
Beat/Miss
Missed by -$0.75
One Year Ago EPS
N/A

Jupiter Neurosciences Revenue Results

Actual Revenue
$0.02 million
Expected Revenue
$0.23 million
Beat/Miss
Missed by -$206.35 thousand
YoY Revenue Growth
N/A

Jupiter Neurosciences Announcement Details

Quarter
Q1 2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Jupiter Neurosciences' next earnings date is estimated for Wednesday, September 2, 2026, based on past reporting schedules.

Conference Call Resources

Jupiter Neurosciences Earnings Headlines

The dollar reset no one told you about
Porter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-year history, back in 1974 with a secret Saudi deal that reshaped an entire generation's wealth. Today, a landmark treaty called Pax Silica - signed by 13 nations in December 2025 and barely covered in the press - is at the center of what Fortune calls 'the biggest change to the world's relationship with the dollar' in a generation. The stocks to buy, the assets to avoid, and the moves to consider are outlined in Stansberry's new briefing.tc pixel
See More Jupiter Neurosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Jupiter Neurosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Jupiter Neurosciences and other key companies, straight to your email.

About Jupiter Neurosciences

Jupiter Neurosciences (NASDAQ:JUNS), a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.

View Jupiter Neurosciences Profile